Cisplatin News and Research

RSS

New insight on ability of certain PAH-derived lesions to evade DNA repair machinery

A person doesn't have to go far to find a polycyclic aromatic hydrocarbon (PAH). These carcinogen precursors are inhaled through automobiles exhaust during the morning commute, are present in a drag of cigarette smoke, and are part of any barbequed meal.

4 Nov 2012

Link between ChemoFx Drug Response Marker results and RFS of cervical cancer patients

A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.

2 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

Few physicians recommend active surveillance for low-risk prostate cancer

Few physicians recommend active surveillance for low-risk prostate cancer rather than pursuing surgery or radiation, according to a Mayo Clinic study being presented at the North Central Section of the American Urological Association's annual meeting Oct. 10-13 in Chicago.

15 Oct 2012

New type of drug for drug-resistant cancer

New drug may be an effective alternative for patients whose cancer is resistant to currently available drugs.

4 Oct 2012

Synthetic hybrid molecules more effectively tackle chemo-resistant cancers

When Linda Tuttle was diagnosed with breast cancer, she never imagined her experience would inspire her colleagues to design new treatments to tackle the disease.

3 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

MiR-214 plays a critical role in regulating ovarian cancer stem cell properties

Researchers at Moffitt Cancer Center have discovered that the micro ribonucleic acid miR-214 plays a critical role in regulating ovarian cancer stem cell properties. This knowledge, said the researchers, could pave the way for a therapeutic target for ovarian cancer.

28 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Platinum tissue concentrations predict NSCLC treatment response

Reduced tissue platinum accumulation might explain why some patients with non-small-cell lung cancer fail to respond to platinum-based chemotherapy, research shows.

13 Sep 2012

Addition of sorafenib to chemotherapy does not prolong survival

The addition of sorafenib to gemcitabine/cisplatin fails to provide any additional benefit in chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer, research shows.

13 Sep 2012

Combination chemotherapy confirmed viable for penile cancer

A combination of cisplatin and 5-fluorouracil is an effective and well-tolerated regimen for patients with squamous cell carcinoma of the penis, show study findings.

12 Sep 2012

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

7 Sep 2012

Bile duct cancer chosen as next indication for PCI Biotech

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has chosen bileduct cancer as the next indication for the use of its PCI (photochemical internalisation) localised cancer therapy. In this indication PCI Biotech’s proprietary photosensitiser Amphinex® will be used in combination with the generic cytotoxic agent gemcitabine. The aim is to start the clinical Proof of Concept study within end of 1H 2013.

21 Aug 2012

Elderly NSC lung cancer patients benefit from concurrent chemoradiation

Fit older adults with locally advanced non-small-cell lung cancer reap similar benefit from concurrent chemoradiation with etoposide and cisplatin as younger patients, but experience higher rates of hospitalization and toxicity, research shows.

8 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012

Study investigates molecular markers in drug-resistant ovarian cancer

A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding of molecular markers in drug-resistant ovarian cancer with a view to improving clinical treatment.

27 Jul 2012